Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients

Table 3 Variations of glutamine, arginie, PGE 2, and acute phasere actents

Variables	Period	Supplemented	Control	P
GLN (nm/mL)	Baseline	558.7 ± 62.5	584.1 ± 51.5	NS
	D 1	386.0 ± 74.6	412.4 ± 65.3	NS
	D 8	722.4 ± 116.5	555.0 ± 72.2	< 0.05
ARG (nm/mL)	Baseline	62.7 ± 21.0	58.5 ± 23.1	NS
	D 1	56.2 ± 18.6	50.9 ± 20.0	NS
	D 8	115.4 ± 47.2	66.7 ± 31.1	< 0.001
PGE2 (pg/mL)	Baseline	62.2 ± 26.4	73.7 ± 42.1	NS
	D 1	167.7 ± 73.8	184.4 ± 91.3	NS
	D 8	85.5 ± 53.0	112.6 ± 84.0	NS
CRP (g/L)	Baseline	0.4 ± 0.1	0.3 ± 0.1	NS
	D 1	4.8 ± 2.3	4.6 ± 1.8	NS
	D 8	2.0 ± 1.1	3.9 ± 2.3	< 0.05
α1-antitrypsin (g/L)	Baseline	15.5 ± 0.2	13.2 ± 0.2	NS
	D 1	42.0 ± 3.4	40.9 ± 4.7	NS
	D 8	28.2 ± 2.8	30.0 ± 3.1	NS
Fibrinogen	Baseline	32.4 ± 3.3	30.6 ± 3.1	NS
	D 1	36.8 ± 4.2	35.5 ± 4.4	NS
	D 8	34.5 ± 3.5	35.0 ± 3.9	NS